Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Elizabeth Rodgers

Nurse Practitioner, Psychiatric/Mental Health Jasper, TN Nurse Practitioner

NPI 1053494708 CMS profile 11188875

215 Hickman Road, Jasper, TN 37347

Open in the dashboard

General payments

$10,166

545 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Elizabeth Rodgers of Jasper, TN is reported in the CMS Open Payments database as having received $10,166 across 545 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,171 97
2024 General $2,374 121
2023 General $1,986 140
2022 General $1,783 130
2021 General $852 57

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elizabeth Rodgers
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Elizabeth Rodgers were reported at $3,171. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Elizabeth Rodgers Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $852 $166 $54–$482 $132
2022 $1,783 $195 $66–$559 $149
2023 $1,986 $233 $82–$673 $160
2024 $2,374 $236 $84–$688 $164
2025 $3,171 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Supernus Pharmaceuticals, Inc. $2,120 157 payments
  2. Janssen Pharmaceuticals, Inc $1,604 21 payments
  3. Teva Pharmaceuticals USA, Inc. $1,087 63 payments
  4. AbbVie, Inc. $1,065 101 payments
  5. Neurocrine Biosciences, Inc. $685 28 payments
  6. Corium, Inc. $656 29 payments
  7. Vanda Pharmaceuticals Inc. $636 35 payments
  8. ITI, Inc. $627 24 payments
  9. Axsome Therapeutics, Inc. $435 18 payments
  10. Alkermes, Inc. $283 13 payments
  11. Other $967 56 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,054 538 payments
  2. Travel and Lodging $981 3 payments
  3. Education $131 4 payments
Products named General payments · program years 2021–2025
  1. SPRAVATO $1,445 16 payments
  2. QELBREE Psychology $1,295 109 payments
  3. VRAYLAR $981 96 payments
  4. Qelbree Viloxazine Hydrochloride $785 45 payments
  5. INGREZZA $662 27 payments
  6. Azstarys $656 29 payments
  7. FANAPT $636 35 payments
  8. Austedo XR $618 37 payments
  9. HETLIOZ $614 33 payments
  10. CAPLYTA $467 19 payments
  11. Other $3,615 180 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 64 drugs

Part D claims

6,980

Median for Nurse Practitioner: 389

Drug cost

$1,018,488

Median for Nurse Practitioner: $21,885

Branded share of claims

22.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Spravato Esketamine Hcl Brand 163 $375,405
Ingrezza Valbenazine Tosylate Brand 20 $175,232
Rexulti Brexpiprazole Brand 76 $116,642
Vraylar Cariprazine Hcl Brand 39 $60,350
Caplyta Lumateperone Tosylate Brand 33 $55,253
Trintellix Vortioxetine Hydrobromide Brand 67 $37,758
Lybalvi Olanzapine/Samidorphan Malate Brand 12 $20,075
Lurasidone Hcl Generic 84 $17,783
Vilazodone Hcl Generic 129 $15,304
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 205 $12,487

The 10 drugs with the highest cost, of 64 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$62,127

Medicare's payments for the services billed

Medicare patients

111

Average age 64

Services billed

1,151

82 women, 29 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 72%
Arthritis 56%
Diabetes 30%
COPD 24%
Chronic kidney disease 23%
Heart failure 15%
Osteoporosis 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qelbree
  • Supernus Pharmaceuticals, Inc. $785
$785 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $245
$245 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $236
$236 20 —
VRAYLAR
  • AbbVie, Inc. $207
$207 39 —
Azstarys
  • Corium, Inc. $200
$200 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

545 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record